ArticleFrontiers in nutrition2025
Association of oxidative balance score with all-cause and cardiovascular mortality among patients with cardio-renal-metabolic disease.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardio-renal-metabolic (CRM) conditions are increasingly recognized as a major public health challenge, with oxidative stress playing a pivotal role in poor prognosis. The oxidative balance score (OBS) is used to assess the body's oxidative stress status, but its link to all-cause and cardiovascular mortality in CRM patients remains unclear. Methods: We used data from participants (≥ 20 years old) in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. The patients were divided into four groups based on OBS using the weighted quartiles method. The relationship between OBS and both all-cause and cardiovascular mortality in CRM patients was assessed using multivariable Cox regression and restricted cubic spline (RCS) models. The differences in cumulative survival between groups were examined using Kaplan-Meier analysis and log-rank tests. Sensitivity analysis and subgroup analysis were also performed. Results: During a median follow-up of 7.9 years, there were 3,838 (25.2%) and 1,412 (8.9%) patients who died from all-cause and cardiovascular mortality, respectively. After adjusting for potential confounders, elevated OBS level was negatively related to the risk of all-cause mortality [Q2, Q3, Q4: adjusted hazard ratio (aHR) (95 confidence interval (CI%)) = 0.85 (0.75-0.96), 0.87 (0.77-0.98), 0.74 (0.62-0.88), respectively; P for trend<0.001]. Moreover, Higher OBS quartiles were linked to a decreased risk of cardiovascular mortality, while no significant reduction was observed in the lower quartiles [model 3: Q2, Q3, Q4: aHR (95CI%) = 0.96(0.77-1.19), 0.78 (0.63-0.97), 0.70 (0.53-0.93), respectively; P for trend = 0.003]. Kaplan-Meier survival analysis also indicated that patients in the highest quartile of OBS had the lowest risk of both all-cause mortality and cardiovascular mortality (log-rank test Conclusion: Elevated levels of OBS were negatively related to the risk of all-cause and cardiovascular mortality among CRM patients, which may offer valuable information on the role of oxidative stress status for risk stratification of mortality in CRM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.